Cost effectiveness of decentralised care model for managing MDR-TB in India

Central TB Division, 2017, 1 Travasso, 2013, Detection and treatment of multidrug resistant TB in India remains low, BMJ, 347 IOM (Institute of Medicine), 2012 Central TB Division, 2012, 1 Vaghela, 2015, Home based care to multi-drug resistant tuberculosis patients: a pilot study, Indian J Tuberc, 62, 91, 10.1016/j.ijtb.2015.04.008 Kabongo, 2010, Effectiveness of home-based directly observed treatment for tuberculosis in Kweneng West subdistrict, Botswana, Afr J Prim Health Care Fam Med, 2, 1 Loveday, 2015, Community-based care vs. centralised hospitalisation for MDR-TB patients KwaZulu-Natal, South Africa, Int J Tuberc Lung Dis, 19, 163, 10.5588/ijtld.14.0369 Celone, 2013, Community-based management of multidrug resistant tuberculosis in rural Kwazulu-Natal, Soc Sci, 12 Ho, 2017, Decentralised care for multidrug-resistant tuberculosis: a systematic review and meta-analysis, Bull World Health Organ, 1 Bassili, 2013, A systematic review of the effectiveness of hospital-and ambulatory-based management of multidrug-resistant tuberculosis, Am J Trop Med Hyg, 89, 271, 10.4269/ajtmh.13-0004 Yin, 2016, Association between directly observed therapy and treatment outcomes in multidrug-resistant tuberculosis: a systematic review and meta-analysis, PLOS ONE, 11, e0150511, 10.1371/journal.pone.0150511 Weiss, 2014, Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis, BMC Infect Dis, 14, 333, 10.1186/1471-2334-14-333 World Health Organization, 2009 World Health Organization, 2014 World Health Organization, 2013 World Health Organization, 2017, 103 Musa, 2016, Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria, Trop Med Int Health, 21, 176, 10.1111/tmi.12648 Central TB Division, 2010, 1 John, 2016, Cost-optimisation in the treatment of multi-drug resistant tuberculosis in India, BMJ Glob Health, 1, A23 Kundu, 2015, Innovative social protection mechanism for alleviating catastrophic expenses on multidrug-resistant tuberculosis patients in Chhattisgarh, India, WHO South-East Asia J Public Health, 4, 69, 10.4103/2224-3151.206624 Williams, 2016, Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis, Global Health Res Policy, 1, 10, 10.1186/s41256-016-0010-y Diel, 2015, Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany, Respir Med, 109, 632, 10.1016/j.rmed.2015.01.017 Guo, 2009, Measuring health-related quality of life in tuberculosis: a systematic review, Health Qual Life Outcomes, 7, 14, 10.1186/1477-7525-7-14 Resch, 2006, Cost-effectiveness of treating multidrug-resistant tuberculosis, PLoS Med, 3, e241, 10.1371/journal.pmed.0030241 Bertram, 2016, Cost-effectiveness thresholds: pros and cons, Bull World Health Organ, 94, 925, 10.2471/BLT.15.164418 India GDP per capita 2017. Available from: https://tradingeconomics.com/india/gdp-per-capita [accessed 25.06.17]. Tupasi, 2006, Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines, PLoS Med, 3, e352, 10.1371/journal.pmed.0030352 Schnippel, 2013, Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa, Trop Med Int Health, 18, 109, 10.1111/tmi.12018 Shin, 2004, Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience, Soc Sci Med, 59, 1529, 10.1016/j.socscimed.2004.01.027 Heller, 2010, Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa, Int J Tuberc Lung Dis, 14, 420 Molla, 2017, The experience of scaling up a decentralised, ambulatory model of care for management of multidrug-resistant tuberculosis in two regions of Ethiopia, J Clin Tuberc Other Mycobact Dis, 7, 28, 10.1016/j.jctube.2017.03.001 Sinanovic, 2015, Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa, Int J Tuberc Lung Dis, 19, 172, 10.5588/ijtld.14.0421 Manabe, 2012, Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis, PLoS ONE, 7, e39187, 10.1371/journal.pone.0039187 World Health Organization, 2011 Joseph, 2011, Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India, Indian J Med Res, 133, 529 Thomas, 2007, Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience, Indian J Tuberc, 54, 117 Udwadia, 2014, Multidrug-resistant-tuberculosis treatment in the Indian private sector: results from a tertiary referral private hospital in Mumbai, Lung India, 31, 336, 10.4103/0970-2113.142101 Law, 2017, Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study, Lancet Public Health, 2, e47, 10.1016/S2468-2667(16)30035-4